@inproceedings{ysebaert:hal-04344799,
TITLE = {Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa},
AUTHOR = {Ysebaert, Loic and Lemonnier, Fran{\c c}ois and Brisou, Gabriel and Casasnovas, Olivier and Pica, Gian Matteo and Bachy, Emmanuel and Fouillet, Ludovic and Abraham, Julie and Guidez, St{\'e}phanie and Andr{\'e},
Marc and Cartron, Guillaume and Gui{\`e}ze, Romain and Carras, Sylvain and Tessoulin, Beno{\^i}t and Houot, Roch and Slama, Bohrane and Bonnet, Christophe and Fornecker, Luc-Matthieu and Delfau-larue, Marie-helene and Sarkozy, Cl{\'e}mentine and Laurent, Camille and Ribrag, Vincent and Morschhauser, Franck},
URL = {https://hal.science/hal-04344799},
BOOK
TITLE = {65th ASH Annual Meeting},
ADDRESS = {San Diego, United States},
VOLUME = {142},
NUMBER = {Supplement 1},
PAGES = {297},
YEAR = {2023},
MONTH = Dec, DOI = {10.1182/blood-2023-185057},
KEYWORDS = {Medicine ; Rituximab ; Internal medicine ; Follicular lymphoma ; Discontinuation ; Clinical endpoint ; CHOP ; Oncology ; Surgery ; Gastroenterology ; Lymphoma ; Clinical trial},
HAL_ID = {hal-04344799},
HAL_VERSION = {v1},
}